Product Name: MARK1 (212-218) pT215
Product Number: PE-04AAT95
Size: 200 µg      Price:39.00
1 mg      $US78.00
5 mg      171.00
Peptide Name: MARK1 (212-218) pT215

Product Use: Services as a blocking peptide for use with the MARK1-pT215 rabbit polyclonal antibody (Cat. No.: AB-PK694) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. This is the major in vivo phosphorylation site in MARK1. T215 phosphorylation stimulates phosphotransferase activity. .

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: NKLD-pT-F

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1032 Da

Peptide Purity Percent after Synthesis and Purification: 95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: MARK1 - pT215 phosphosite-specific antibody (Cat. No.: AB-PK694)

Scientific Background: MARK1 is a protein-serine/threonine kinase that is is a member of the CAMK group of protein kinases in the CAMKL family, and MARK subfamily. It mediates control of cell polarity and microtubule function. This kinase is highly expressed and widely distributed in most tested human tissues except apparently in the brain and spinal cord. It is activated by phosphorylation on T215 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. MARK1 phosphorylates microtubule-associated proteins and trigger microtubule disruption. Gene mutation studies performed in mice revealed that after targeted disruption of the MARK1 gene, the mice lacked the ability to drink, and displayed hind leg motor dysfunction. Genetic variations in MARK1 have been correlated with susceptibility to autism. MARK1 is over-expressed in the prefrontal cortex of autism patients and affects the function of cortical dendrites. MARK1 has also been linked with the development of gastric adenocarcinomas and ovarian serous carcinomas.